Summit Therapeutics is trading 4.12% higher at $17.70 as U.S. equities advance following August inflation data and improving risk appetite.
- Major indexes are up more than 0.5%, providing a supportive backdrop for biotechnology stocks.
- No new, clearly confirmed company-specific announcement on September 11, 2026 explains the move.
- Recent momentum remains supported by Jefferies’ September 9 upgrade to Buy and positive ivonescimab clinical data.